XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 9 - Investment in Conduit Pharmaceuticals (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 22, 2024
Sep. 30, 2023
Sep. 22, 2023
Jan. 26, 2023
Feb. 07, 2022
Jan. 07, 2022
Jul. 12, 2021
Feb. 28, 2023
Dec. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Sep. 21, 2023
May 11, 2023
Mar. 01, 2023
Special Purpose Acquisition Company (SPAC) [Member]                            
Financing Receivable, before Allowance for Credit Loss     $ 1,000,000                      
Murphy Canyon Acquisition Sponsor, LLC [Member]                            
Intangible Assets, Net (Excluding Goodwill)                         $ 5,000,001  
Investment Income, Net                   $ 664,232        
Deconsolidation, Gain (Loss), Amount     6,200,000           $ 40,300,000          
Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount     $ 34,100,000                      
Conduit Pharmaceuticals Inc [Member]                            
Stock Issued During Period, Shares, New Issues (in shares)     754,000                      
Stock Issued During Period, Shares, Acquisitions (in shares)     65,000,000                      
Conduit Pharmaceuticals Inc [Member] | Director [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   45,000 45,000                      
Stock Issued During Period, Shares, Issued for Services (in shares)   45,000 45,000                      
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 540,000   754,000                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 3.12                          
Warrants and Rights Outstanding, Term (Year) 2 years                          
Warrant or Right, Exercisable Period (Year) 1 year                          
Conduit Pharmaceuticals Inc [Member] | Conversion of Class B to Class A Common Stock [Member]                            
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)     3,306,250                      
Common Class A [Member]                            
Stock Subject to Possible Redemption, Shares (in shares)                           2,187,728
Stock Issued During Period, Shares, New Issues (in shares)             1,000,000              
Common Class A [Member] | Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)     754,000                      
Trust for the SPAC Class A Common Stockholders [Member]                            
Cash Withdrawn From Trust Account                     $ 114,100,000      
Trust Account, Income Tax Withdraws               $ 200,050            
Trust Account, Extension Payments               $ 155,403            
Investments                     $ 23,300,000      
Conduit Pharmaceuticals Inc [Member]                            
Investment Owned, Fair Value                   4,400,000        
Investment Owned, Cost                   $ 7,500,000        
Lock-up Agreement, Shares (in shares) 2,700,000                          
Investment Owned, Balance, Shares (in shares) 4,015,250                          
Conduit Pharmaceuticals Inc [Member] | Common Stock [Member]                            
Investment Owned, Fair Value Per Share (in dollars per share)                   $ 1.06        
Conduit Pharmaceuticals Inc [Member] | Warrant [Member]                            
Investment Owned, Fair Value Per Share (in dollars per share)                   0.039        
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                            
Investment Owned, Fair Value Per Share (in dollars per share)                   $ 0.29        
The “Merger Consideration” [Member]                            
Stock Redeemed or Called During Period, Shares (in shares)       11,037,272                    
Special Purpose Acquisition Company (SPAC) [Member]                            
Subsidiary, Ownership Percentage, Parent                       65.00%    
Conduit Pharmaceuticals Inc [Member]                            
Investment Owned, Net Assets, Percentage   6.50% 6.50%             6.30%        
SPAC, Initial Public Offering [Member] | Murphy Canyon Acquisition Sponsor, LLC [Member]                            
Proceeds from Issuance of Common Stock         $ 132,250,000 $ 132,250,000                
Subsidiary, Ownership Percentage, Parent           23.50%                
Units Issued During Period, Units, New Issues (in shares)         13,225,000 132,250,000                
SPAC Units, Composition, Number of Shares Per Unit (in shares)           1                
SPAC, Placement Units, Number of Units Purchased (in shares)         754,000                  
SPAC, Placement Units, Price Per Share (in dollars per share)         $ 10                  
SPAC, Purchase Units, Payments for the Purchase of Equity         $ 7,540,000                  
Stock Issuance Costs         7,738,161                  
Underwriting Discounts and Commission         2,645,000                  
Deferred Underwriting Fees         4,628,750                  
Other Equity Offering Costs         $ 464,411